The availability of medicines post-Brexit in Malta

AdobeStock_725720725 (1)

Following the EU Referendum decision in June 2016, the United Kingdom (UK) officially left the European Union (EU), and its single market and customs union on 31 January 2020. Since the UK now has third country status with regard to dealings with the EU, restricted availability of medicinal products from the UK across EU member states (MS) is expected. Smaller MS, such as Malta, have historically sourced medicinal supplies from the UK. The lack of availability or insufficient supply of medicines represents a significant obstacle to patients’ access to medicines.

Within this article, we investigated how Brexit has affected medicines availability in Malta, namely, to identify which medicines are not available post-Brexit and to recognise experiences of different pharmaceutical sectors involved in the supply chain when it comes to medicine availability post-Brexit. A total of 542 marketing authorisations (MA) with the MA holder based in the UK were withdrawn, and a total of 544 MA became invalidated as MA from the UK since they no longer met EU legislative requirements.

Poor medicines availability has a clear negative downside on econan levels which are especially relevant to MS, such as Malta with smaller pharmaceutical markets, where lack of availability of medicines is a problem. Ultimately, sourcing medicines from other EU MS would allow greater availability of medicines.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.


Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

  • Create your own library to save your favourite content.
Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.



Special offer on
TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £290.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends 31 July 2024

Become a member